Compagnie Lombard Odier SCmA’s Insys Therapeutics, Inc. INSY Stock Holding History

Compagnie Lombard Odier SCmA’s Portfolio INSY Stock Details INSY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-5,000	Closed	-$23K	–	622
2019 Q1	$23K	Hold	5,000	–	–	﹤0.01%	459
2018 Q4	$17K	Buy	5,000 +4,000	+400%	+$27.8K	﹤0.01%	461
2018 Q3	$10K	Sell	1,000 -2,000	-67%	-$16K	﹤0.01%	514
2018 Q2	$22K	Hold	3,000	–	–	﹤0.01%	522
2018 Q1	$18K	Sell	3,000 -3,000	-50%	-$24.8K	﹤0.01%	532
2017 Q4	$58K	Buy	6,000 +3,000	+100%	+$19.6K	﹤0.01%	531
2017 Q3	$27K	Buy	+3,000	New	+$31K	﹤0.01%	586
2015 Q2	–	Sell	-2,000	Closed	-$58K	–	964
2015 Q1	$58K	Buy	+2,000	New	+$52.9K	﹤0.01%	768

Other funds holding INSY

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

KBC Group Brussels, Belgium $39.9B AUM 29.7% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

Compagnie Lombard Odier SCmA's INSY Position: Q2 2019 in Review

Compagnie Lombard Odier SCmA sold out of Insys Therapeutics, Inc. (INSY) in Q2 2019, closing a stake of 5,000 shares — an estimated $23K sold.

Compagnie Lombard Odier SCmA first reported a position in INSY in Q1 2015 and held it in 8 quarters. The position peaked at $58K in Q4 2017. 16 funds tracked by Wall St. Rank hold INSY as of Q2 2019.

Compagnie Lombard Odier SCmA reported no remaining Insys Therapeutics, Inc. position as of Q2 2019 after selling out during the quarter.
Compagnie Lombard Odier SCmA sold 5,000 Insys Therapeutics, Inc. shares in Q2 2019, an estimated $23K.
Compagnie Lombard Odier SCmA first reported a position in Insys Therapeutics, Inc. in Q1 2015 and held it in 8 quarters.
Compagnie Lombard Odier SCmA's Insys Therapeutics, Inc. position peaked at $58K in Q4 2017.
16 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q2 2019.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q2 2019, filed 14 Aug 2019.